Skip to main content
. 2020 May 28;53(6):e12818. doi: 10.1111/cpr.12818

FIGURE 4.

FIGURE 4

Oip5‐as1 functions as a ceRNA of miR‐29a. A, Prediction of Oip5‐as1 binding sites in miR‐29a and the Ago2 protein using the StarBase and DIANA‐LncBase databases. B, RT‐qPCR analysis of Oip5‐as1 and miR‐29a enrichment by Ago2 antibody and IgG antibody in RNA immunoprecipitation experiments. C, The sequences and positions of Oip5‐as1 containing the wild type and mutant binding sites of miR‐29a cloned into the pmirGLO luciferase reporter vectors. D, Luciferase activity in HEK293T cells co‐transfected with the reporter plasmid inserted with the wild‐type or mutated Oip5‐as1 sequences and miR‐29a mimics or mimic‐NC. E, Determination of knockdown efficiency for three siRNAs towards Oip5‐as1 (si‐Oip5‐as1) in H9c2 cells by RT‐qPCR. The Oip5‐as1 siRNA (3) was applied in all experiments. F, Relative level of miR‐29a expression in H9c2 cells transfected with the overexpression vector or siRNA of Oip5‐as1 and the corresponding negative control (NC). G, Relative levels of miR‐29a expression in H9c2 cells transfected with mimics or inhibitors and their corresponding NCs by RT‐qPCR analysis. H, Relative levels of Oip5‐as1 expression in H9c2 cells transfected with miR‐29a mimics or inhibitors. Data are expressed as mean ± SD (n = 3). *P < .05 vs the IgG, mimic‐NC, inhibitor‐NC or si‐NC groups